| March 28, 2013 | ISSUE NUMBER 294 VOL 10 |
Legal
What’s the FTC’s Problem with Pay for Delay?
This week the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive. But what exactly is the FTC so worried about? ...Read more
Cegedim Relationship Management
Sunshine Act – Final Regulations and Best Practices for Compliance
The new transparency requirements of the Sunshine Act will require manufacturers of drugs, medical devices, and medical supplies to collect data on almost all payments made to physicians, teaching hospitals, and group purchasing organizations starting August 1, 2013.
To get a summary of the final regulations and learn best practices for compliance
 Click here
Legal
Pay for Delay: Not in Pharma’s Best Interests
Traci Medford-Rosow and Peter C. Richardson spent over 30 years of their professional lives working for Big Pharma, many as Chief IP Counsels defending patents. Here, they explain why they believe that pay-for-delay provisions are not in the best interests of the research-based industry ...Read More
Digital Pharma
Social Media Guidelines: In Pursuit of a Policy
You don’t have a social media policy yet? Oh, you do, you just didn’t tell your staff? Peter Houston takes a cross-industry look at the faltering progress of social media guidelines and finds that pharma isn’t doing any worse in this area than other business sectors ...Read more
Engage Nurse Practitioners through their Trusted Destination: Generation NP Communicate. Collaborate. Educate
Live Webcast: Tuesday, March 26, 2013 from 11:00am–12:00pm ET
Register Free at:
 www.pharmexec.com/generationNP
Global
Healthcare Systems in Europe “Failing Patients”
Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault at a conference in Dublin, Ireland, when one highly articulate cancer patient took the European healthcare to task ...Read more
New Models of Cancer Research in the Age of Personalized Medicine
Live Webcast: Wednesday, April 17, 2013 at 11:00 am EDT
Register Free at:
 www.pharmexec.com/personalized
Global
Read the Latest Pharm Exec Global Digest
In this month’s issue: Seeing through EU Pricing Transparency; Global Patent Management Made Easy; Multichannel Pharma Marketing; Harnessing Positive Content for Reputation Management ...Read more
|
|
|
 // Former AstraZeneca Vice President Dr Deborah Hartman joined Avaxia Biologics as VP, Research, replacing Dan Tracey who retires. // The former Head of R&D at Pfizer, Dr John LaMattina, joined UK-based biotech Ziarco. // The Dow Chemical Company (Midland, MI) announced that Marc van Gerwen has been named Global Business Director for Dow Pharma & Food Solutions.//CRO Theorem Clinical Research (King of Prussia, PA) announced the appointment of Sara Davis as VP, Global Business Development.// |
|
|
From Focus Reports Ltd., and
Pharm Exec: learn how to do business in Brazil
Last to enter the financial crisis and first to emerge, Brazil has created a new block of middle-class "pharmerging" consumers. Learn key drivers with rapid growth in this ninth-largest market. Report includes key economic data, interviews, and company directory. Download the PDF now.
|
|
|
|
|
 |
|
 |
|
 |
|
 |
How optimistic are you about your company achieving revenue growth in 2013?
|
|
|
|
